Economic Burden of Colorectal Cancer in Korea.
- Author:
Ju Young BYUN
1
;
Seok Jun YOON
;
In Hwan OH
;
Young Ae KIM
;
Hye Young SEO
;
Yo Han LEE
Author Information
1. Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea. yoonsj02@korea.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Cost of illness;
Economic burden;
Colorectal neoplasms;
Prevalence
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Child;
Child, Preschool;
Colorectal Neoplasms/*economics/epidemiology;
*Cost of Illness;
Female;
Health Care Costs;
Health Expenditures;
Humans;
Infant;
Infant, Newborn;
Male;
Middle Aged;
Prevalence;
Republic of Korea;
Young Adult
- From:Journal of Preventive Medicine and Public Health
2014;47(2):84-93
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: The incidence and survival rate of colorectal cancer in Korea are increasing because of improved screening, treatment technologies, and lifestyle changes. In this aging population, increases in economic cost result. This study was conducted to estimate the economic burden of colorectal cancer utilizing claims data from the Health Insurance Review and Assessment Service. METHODS: Economic burdens of colorectal cancer were estimated using prevalence data and patients were defined as those who received ambulatory treatment from medical institutions or who had been hospitalized due to colorectal cancer under the International Classification of Disease 10th revision codes from C18-C21. The economic burdens of colorectal cancer were calculated as direct costs and indirect costs. RESULTS: The prevalence rate (per 100 000 people) of those who were treated for colorectal cancer during 2010 was 165.48. The economic burdens of colorectal cancer in 2010 were 3 trillion and 100 billion Korean won (KRW), respectively. Direct costs included 1 trillion and 960 billion KRW (62.85%), respectively and indirect costs were 1 trillion and 160 billion (37.15%), respectively. CONCLUSIONS: Colorectal cancer has a large economic burden. Efforts should be made to reduce the economic burden of the disease through primary and secondary prevention.
